REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights
REGENXBIO (Nasdaq: RGNX) has scheduled a conference call for Monday, May 12, at 4:30 p.m. ET to present its financial performance for the first quarter ending March 31, 2025, along with recent operational updates.
The company has provided two access options for interested parties:
- General listeners can join via a webcast link
- Analysts can participate in the Q&A session through a separate dedicated link
A recording of the webcast will be made available on REGENXBIO's investor website approximately two hours after the call concludes. Participants are encouraged to connect 15 minutes before the scheduled start time.
REGENXBIO (Nasdaq: RGNX) ha programmato una conference call per lunedì 12 maggio alle 16:30 ET per presentare i risultati finanziari del primo trimestre terminato il 31 marzo 2025, insieme agli aggiornamenti operativi più recenti.
L'azienda ha messo a disposizione due modalità di accesso per gli interessati:
- Gli ascoltatori generali possono partecipare tramite un link webcast
- Gli analisti possono intervenire nella sessione di domande e risposte attraverso un link dedicato separato
La registrazione del webcast sarà disponibile sul sito degli investitori di REGENXBIO circa due ore dopo la conclusione della chiamata. Si consiglia ai partecipanti di collegarsi 15 minuti prima dell'orario previsto.
REGENXBIO (Nasdaq: RGNX) ha programado una conferencia telefónica para el lunes 12 de mayo a las 4:30 p.m. ET para presentar su desempeño financiero del primer trimestre que finalizó el 31 de marzo de 2025, junto con actualizaciones operativas recientes.
La compañía ha ofrecido dos opciones de acceso para los interesados:
- Los oyentes generales pueden unirse a través de un enlace de webcast
- Los analistas pueden participar en la sesión de preguntas y respuestas mediante un enlace dedicado separado
Una grabación del webcast estará disponible en el sitio web para inversores de REGENXBIO aproximadamente dos horas después de que finalice la llamada. Se recomienda a los participantes conectarse 15 minutos antes de la hora programada.
REGENXBIO (나스닥: RGNX)는 2025년 3월 31일에 종료된 1분기 재무 실적과 최근 운영 업데이트를 발표하기 위해 5월 12일 월요일 오후 4시 30분 ET에 컨퍼런스 콜을 예정했습니다.
회사는 관심 있는 분들을 위해 두 가지 접속 옵션을 제공했습니다:
- 일반 청취자는 웹캐스트 링크를 통해 참여할 수 있습니다
- 애널리스트는 별도의 전용 링크를 통해 질의응답 세션에 참여할 수 있습니다
웹캐스트 녹화본은 콜 종료 약 2시간 후 REGENXBIO 투자자 웹사이트에서 제공될 예정입니다. 참가자들은 예정된 시작 시간 15분 전에 접속할 것을 권장합니다.
REGENXBIO (Nasdaq : RGNX) a programmé une conférence téléphonique pour le lundi 12 mai à 16h30 ET afin de présenter ses résultats financiers du premier trimestre clos le 31 mars 2025, ainsi que les dernières mises à jour opérationnelles.
L'entreprise propose deux options d'accès pour les intéressés :
- Les auditeurs généraux peuvent se connecter via un lien webcast
- Les analystes peuvent participer à la séance de questions-réponses via un lien dédié séparé
Un enregistrement du webcast sera disponible sur le site des investisseurs de REGENXBIO environ deux heures après la fin de l'appel. Il est conseillé aux participants de se connecter 15 minutes avant l'heure prévue.
REGENXBIO (Nasdaq: RGNX) hat für Montag, den 12. Mai, um 16:30 Uhr ET eine Telefonkonferenz angesetzt, um die Finanzergebnisse des ersten Quartals zum 31. März 2025 sowie aktuelle betriebliche Updates vorzustellen.
Das Unternehmen bietet zwei Zugangsmöglichkeiten für Interessierte an:
- Allgemeine Zuhörer können über einen Webcast-Link teilnehmen
- Analysten können über einen separaten, speziellen Link an der Fragerunde teilnehmen
Eine Aufzeichnung des Webcasts wird etwa zwei Stunden nach Ende des Calls auf der Investorenseite von REGENXBIO verfügbar sein. Teilnehmer werden gebeten, sich 15 Minuten vor Beginn einzuwählen.
- None.
- None.
Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.
ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-may-12-to-discuss-first-quarter-2025-financial-results-and-recent-operational-highlights-302443092.html
SOURCE REGENXBIO Inc.
FAQ
When is REGENXBIO (RGNX) releasing Q1 2025 earnings?
How can I listen to REGENXBIO's Q1 2025 earnings call?
What time should I join REGENXBIO's May 12 earnings call?
Where can I find the replay of RGNX Q1 2025 earnings call?
How can analysts participate in RGNX's Q1 2025 earnings Q&A session?
